240
Participants
Start Date
March 8, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
November 30, 2026
LSALT Peptide
LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
Placebo
0.9% saline solution
RECRUITING
Kosuyolu High Specialization Training and Research Hospital, Kartal
RECRUITING
Erciyes University, Faculty of Medicine - Semiha Kibar Organ Transplant & Dialysis Hospital, Melikgazi
RECRUITING
Kocaeli University, Faculty of Medicine Practices and Research Hospital, İzmit
RECRUITING
Sütçü İmam University, Faculty of Medicine, Kahramanmaraş
RECRUITING
Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary, Calgary
NOT_YET_RECRUITING
Unity Health Toronto, St. Michael's Hospital, Toronto
RECRUITING
University Health Network, Toronto General Hospital, Toronto
RECRUITING
Gazi University, Yenimahalle
Lead Sponsor
Arch Biopartners Inc.
INDUSTRY